Supplements

GoodRx Reports First Quarter 2024 Results

Retrieved on: 
Jeudi, mai 9, 2024
Managed Care, Men, General Health, Online Retail, Family, Specialty, Consumer, Health Insurance, Retail, Women, Seniors, Vitamins, Supplements, Health, Net income, Macs, Partnership, Income tax, Share repurchase, Marketing, Adjustment, Interim, Advertising, GoodRx, GAAP, Growth, Pharmaceutical industry

GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024.

Key Points: 
  • GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx,” or the “Company”), the leading destination for prescription savings in the U.S., has released its financial results for the first quarter of 2024.
  • For the first quarter of 2024, revenue, the most directly comparable financial measure calculated in accordance with GAAP, was equal to Adjusted Revenue and we expect revenue to equal Adjusted Revenue for the second quarter and full year of 2024.
  • As of March 31, 2024, GoodRx had cash and cash equivalents of $533.3 million and total outstanding debt of $658.3 million.
  • During the first quarter of 2024, we repurchased 21.3 million shares of Class A common stock for an aggregate of $154.8 million.

ChromaDex Corporation Reports First Quarter 2024 Financial Results

Retrieved on: 
Mercredi, mai 8, 2024
Health, Fitness & Nutrition, Other Science, General Health, Science, Vitamins, Supplements, Biotechnology, Sprouts, Investment, The Vitamin Shoppe, Dietary supplement, WalletHub, ChromaDex, Annual report, Security (finance), Tru, Conference, Research, Replay, Webcast, Farmer, History, Herbal, Farmers' market, Sprouts Farmers Market, Marketing, Adjustment, GAAP, Growth, Video game

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024.
  • Net loss was $0.5 million or $(0.01) per share, a $1.4 million improvement, or $0.02 per share, from the prior year quarter.
  • Adjusted EBITDA, a non-GAAP measure, improved to a positive $0.7 million from a negative $0.1 million in the prior year quarter.
  • In April 2024, ChromaDex expanded distribution of Tru Niagen®, announcing partnerships with The Vitamin Shoppe and Sprouts Farmers Market, both targeting health-conscious consumers.

Nu Skin Enterprises Announces Quarterly Dividend

Retrieved on: 
Mercredi, mai 8, 2024
Other Health, Other Retail, Lifestyle, Consumer, Cosmetics, Fitness & Nutrition, Retail, Other Consumer, Women, Alternative Medicine, Vitamins, Supplements, Health, Nu Skin Enterprises, NUS

Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 12, 2024, to shareholders of record on May 31, 2024.

Key Points: 

Nu Skin Enterprises, Inc. (NYSE: NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 12, 2024, to shareholders of record on May 31, 2024.

Laird Superfood Reports First Quarter 2024 Financial Results

Retrieved on: 
Mercredi, mai 8, 2024
Other Retail, Sustainability, Supermarket, Specialty, Electronic Commerce, Technology, Food, Beverage, Environment, Fitness & Nutrition, Retail, Vitamins, Supplements, Health, DTC, Amazon, LSF, Food industry, Marketing, Accounting, G&A, Growth, Pharmaceutical industry

Laird Superfood, Inc. (NYSE American: LSF) (“Laird Superfood,” the "Company", “we”, and “our”), today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Laird Superfood, Inc. (NYSE American: LSF) (“Laird Superfood,” the "Company", “we”, and “our”), today reported financial results for the first quarter ended March 31, 2024.
  • Anya Hamill, Chief Financial Officer, commented, "Laird Superfood’s first quarter financial results showcase our team’s work against our strategic initiatives.
  • Our full year guidance reflects the confidence that we have in our near-term financial results as well as the long-term strategies and financial future of Laird."
  • For more details on non-GAAP financial measures, refer to the information in the non-GAAP financial measures section of this press release.

Nu Skin Enterprises Reports First Quarter Results

Retrieved on: 
Mercredi, mai 8, 2024
Alternative Medicine, Health, Lifestyle, Vitamins, Supplements, Consumer, Fitness & Nutrition, Cosmetics, Retail, Piramal Group, Acquisition, Ecosystem, Growth

“We are continuing our business transformation efforts and making progress in developing our integrated beauty, wellness and lifestyle ecosystem.

Key Points: 
  • “We are continuing our business transformation efforts and making progress in developing our integrated beauty, wellness and lifestyle ecosystem.
  • During the quarter, we again drove strong gains in our Rhyz business, growing nearly 60% year-over-year.
  • In our Nu Skin core business, the macro-economic environment impacted affiliate and customer growth around the globe, but we are encouraged by the performance of our ageLOC WellSpa iO, RenuSpa iO and TRMe launches.
  • We also introduced some new early affiliate rewards and top leader incentives to help drive customer acquisition and business growth.

Biote Reports First Quarter 2024 Financial Results

Retrieved on: 
Mardi, mai 7, 2024
Biotechnology, Vitamins, Supplements, Other Health, Health, Pharmaceutical, International, Depreciation, Regulation S-K, Conference, Webcast, Forecasting, Exercise, Tax, Patient, Acquisition, Regulation, Judgement, Telephone, GAAP, Growth, Earnout, Bookkeeping

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024.
  • Revenue for the first quarter of 2024 was $46.8 million, an increase of 4.4% from $44.8 million for the first quarter of 2023.
  • Gross profit margin for the first quarter of 2024 was 71.4% compared to 69.1% for the first quarter of 2023.
  • Operating income for the first quarter of 2024 was $10.4 million, compared to $7.9 million for the first quarter of 2023.

Longevity Biotech, Timeline, Leads the Way in Healthy Aging Research with Groundbreaking Clinical Studies

Retrieved on: 
Lundi, mai 6, 2024
Biotechnology, Other Health, Diabetes, Health, Biometrics, Oncology, Vitamins, Supplements, Research, Fitness & Nutrition, Science, Clinical Trials, Cancer, Oxidative stress, American Association of Immunologists, MD, Urolithin A, Trial of the century, Doctor of Philosophy, Entrepreneurship, Prostate cancer, Neoplasm, AAI, Patient, Infection, Notifiable disease, Immune system, Longevity, CD8

Additionally, the company has partnered on two new clinical trials in collaboration with prestigious research institutions to expand its applications of Mitopure for healthy aging.

Key Points: 
  • Additionally, the company has partnered on two new clinical trials in collaboration with prestigious research institutions to expand its applications of Mitopure for healthy aging.
  • Timeline, backed by Nestlé and L'Oréal Group investments, builds on 15 years of research and multiple clinical studies.
  • "Our mission has always been to pioneer research that unlocks clinically proven interventions to help people stay healthier for longer.
  • These results open a totally new approach to directly impact our immune cells and help restore their functionality during aging."

Beachbody (BODi) Reports Q1 2024 Cash Flow from Operations of $9.1 Million and the First Sequential Quarterly Revenue Growth Since 2021

Retrieved on: 
Lundi, mai 6, 2024
Health, Consumer, Women, Fitness & Nutrition, General Health, Men, Vitamins, Supplements, Digital, Total, Nutrition, Three Months, Operating cost, Cryptocurrency

Total revenue was $120.0 million compared to $144.9 million in the prior year period.

Key Points: 
  • Total revenue was $120.0 million compared to $144.9 million in the prior year period.
  • Digital revenue was $61.5 million compared to $64.8 million in the prior year period and digital subscriptions totaled 1.22 million in the first quarter.
  • Operating loss improved by $16.6 million to $10.8 million compared to an operating loss of $27.4 million in the prior year period.
  • Free cash flow was $7.4 million compared to $(11.3) million in the prior year period.

ästhetik skincare Founder Alexis Pfropper Named a Winner for Season 1 of the 2024 TITAN Women in Business Awards

Retrieved on: 
Jeudi, mai 2, 2024
Other Health, Professional Services, Entrepreneur, Business, Specialty, Consumer, Fashion, Cosmetics, Retail, Women, Alternative Medicine, Vitamins, Supplements, Health, IAA, Woman, Female, Love, Growth, Gold Award, Gold, Organization, Film industry

Pfropper promoted her extraordinary achievements globally to business sectors worldwide, accomplishing great success for their grand titles for this year.

Key Points: 
  • Pfropper promoted her extraordinary achievements globally to business sectors worldwide, accomplishing great success for their grand titles for this year.
  • “It is an honor to be recognized with a TITAN Award, especially alongside so many incredible women entrepreneurs, founders and other business leaders,” shared Pfropper.
  • Born from Pfropper’s frustration with current consumer skincare products as an esthetician and spa owner, ästhetik skincare offers clean, plant-based and sustainable skincare products.
  • Committed to fairness and diversity, the TITAN Women In Business Awards has invited an esteemed panel of judges, consisting of professionals from notable organizations.